Biosensor

Biosensor is an analytical device that combines a biological recognition element — such as an enzyme, antibody, nucleic acid, or whole cell — with a physicochemical transducer to convert a biological input into a measurable signal. The output is typically electrical, optical, or thermal in nature, and can be quantified to determine the presence or concentration of a target substance. Originally developed for clinical diagnostics, biosensor technology has expanded dramatically into military, environmental, and — according to a growing body of researchers — covert surveillance applications. The convergence of biosensors with nanotechnology, wireless communication, and the Internet of Bodies has raised serious questions about undisclosed deployment of biosensing components via pharmaceutical products and the implications for bodily autonomy and population-level biological monitoring.

A glucose meter exemplifies a common electrochemical biosensor, converting biochemical glucose binding into quantifiable electrical signals.

How a Biosensor Works

A biosensor consists of two core components:

• Biological recognition element — a molecule or living system that selectively binds to or reacts with the target analyte. Common examples include enzymes (which catalyse a reaction), antibodies (which bind antigens), aptamers (synthetic nucleic acids that bind target molecules), and whole cells or tissues.
• Transducer — converts the biological response into a measurable physicochemical signal. Transducers may be electrochemical, optical, piezoelectric, or thermal.

The signal produced is amplified, processed, and read out — either locally or transmitted wirelessly to an external device.

Types of Biosensors

Example of a modern electrochemical biosensor: a continuous glucose monitor (CGM) device, one of the most widespread biosensor applications in clinical use.

Electrochemical

A typical electrochemical glucose biosensor (blood glucose monitor), the most widely deployed biosensor type in consumer healthcare. The electrode surface detects enzymatic reactions to measure glucose concentration.

The most widely deployed type. Electrochemical biosensors measure the electrical change produced by a biochemical reaction at an electrode surface. Amperometric sensors measure current; potentiometric sensors measure voltage; impedimetric sensors measure changes in electrical impedance. The standard blood glucose monitor is an amperometric electrochemical biosensor. Graphene-based materials have become a favoured electrode substrate due to their extraordinary surface area, electrical conductivity, and biocompatibility — properties that also make them candidates for nano-scale, in-body deployment.

Optical

Optical biosensors use changes in light properties — absorption, fluorescence, surface plasmon resonance — to detect biological events. Surface plasmon resonance (SPR) biosensors are widely used in pharmaceutical research to study protein interactions. Fluorescent optical biosensors can be engineered to operate inside living cells.

Two classes of nanomaterial have become particularly significant in optical biosensor development:

• IR Quantum Dots — semiconductor nanocrystals engineered to absorb and emit light in the near-infrared spectrum. Their photostability (resistance to photobleaching), spectrally tunable emission, and ability to function in the near-infrared optical window of biological tissue — where light penetrates several centimetres with minimal scattering — make them highly attractive for implantable and injectable biosensor configurations. IR quantum dots can be functionalised with biological recognition elements and embedded in injectable formulations, enabling in-body optical sensing that can be interrogated transcutaneously using external near-infrared illumination sources. This combination is actively explored for continuous glucose monitoring, tumour microenvironment sensing, and — in DARPA-funded research — real-time physiological monitoring without a tethered device. Their persistence and spectral specificity allow multiplexed detection of several analytes simultaneously from a single injection site, making them compelling candidates for the Internet of Bodies sensor layer. The Nanotoxicology of IR quantum dots remains an active area of concern: heavy-metal-core varieties (cadmium selenide, lead sulphide) carry recognised cytotoxic risks, and their long-term fate in biological tissue is not fully characterised.

• Carbon Quantum Dots (CQDs) — a younger class of fluorescent nanomaterial derived from carbon precursors, including citric acid, glucose, and plant matter. Carbon quantum dots are increasingly studied as a lower-toxicity alternative to heavy-metal quantum dots for biosensing applications. They exhibit bright, tuneable fluorescence, high water solubility, and surface chemistry amenable to functionalisation with antibodies, aptamers, and other recognition elements. CQDs have demonstrated capacity for multiplexed detection — simultaneously identifying multiple biomarkers, heavy metal ions, and pathogens in a single assay — at sensitivities reaching picomolar and femtomolar concentrations. Their relatively benign toxicological profile (see Nanotoxicology) makes them attractive for injectable and ingestible biosensor configurations where long-term biocompatibility is a concern. Independent researchers have noted that carbon-based fluorescent nanostructures observed in some pharmaceutical preparations are consistent with CQD morphology, though this interpretation is contested.

Piezoelectric

Piezoelectric biosensors detect mass changes on a crystal surface caused by analyte binding. Quartz crystal microbalance (QCM) devices can detect binding events at nanogram sensitivity. These are used in pathogen detection and environmental monitoring.

Thermal (Calorimetric)

Calorimetric biosensors measure the heat released or absorbed during a biochemical reaction. They are particularly useful where enzymatic reactions are involved. Although less common in consumer devices, they have applications in industrial fermentation monitoring and point-of-care diagnostics.

Medical and Research Applications

Continuous glucose monitor (CGM) device: a practical example of an implantable electrochemical biosensor used in clinical settings to monitor blood glucose levels in real-time.

Mainstream biosensor applications are well-documented and span a wide range of clinical and research contexts:

• Continuous Glucose Monitors (CGMs) — subcutaneous electrochemical biosensors that continuously sample interstitial glucose levels and transmit data wirelessly to a smartphone or receiver. Devices such as the Dexcom G7 and Abbott FreeStyle Libre represent mass-market implantable biosensor platforms already operating inside tens of millions of human bodies.
• Implantable Cardiac Monitors (ICMs) — small devices inserted under the skin to continuously monitor cardiac rhythm for up to three years, transmitting data remotely to clinical systems.
• Lab-on-Chip — miniaturised biosensor arrays integrated onto a single microchip capable of performing multiple simultaneous assays from a tiny fluid sample. These underpin rapid diagnostic tests and are being developed for battlefield triage and remote population screening.
• Point-of-Care (POC) diagnostics — biosensor strips and cartridges used in emergency rooms, GP surgeries, and field environments for rapid detection of pathogens, cardiac markers, and drug levels.
• Environmental monitoring — biosensors deployed in water systems, soil, and air to detect pollutants, pathogens, or chemical agents.

DARPA and Military Biosensor Research

The Defense Advanced Research Projects Agency has invested heavily in biosensor development for military and intelligence applications, often with implications extending well beyond the battlefield.

DARPA Persistent Aquatic Living Sensors (PALS)

Launched in 2018, the PALS programme sought to exploit the natural sensing capabilities of marine organisms — fish, crustaceans, molluscs — as persistent environmental biosensors. The premise was that living organisms respond to underwater stimuli (submarines, divers, vessels) in ways that can be monitored and decoded. DARPA researchers aimed to develop interfaces capable of reading these biological responses and transmitting them as actionable intelligence. PALS represents a broader DARPA philosophy: that living organisms are more sensitive, more energy-efficient, and more adaptable than man-made sensors for certain detection tasks.

Other DARPA Biosensor Initiatives

• Electrical Prescriptions (ElectRx) — a DARPA programme developing ultra-miniature implantable biosensors and neurostimulators to monitor and modulate peripheral nerve function, ostensibly for treating disease, but developing core technology for closed-loop biological monitoring and intervention.
• Biochronicity — research into biological timing mechanisms and circadian rhythm monitoring as biosensor signals.
• In Vivo Nanoplatforms (IVN) — seeking to develop nanoparticle-based systems capable of residing within the body and sensing physiological or chemical changes, reporting wirelessly.
• Soldier-worn and implantable biosensors for real-time monitoring of combat stress hormones, blood chemistry, hydration, and wound status have been actively developed through DARPA Human Enhancement Programmes.

The Department of Defence has explicitly framed in-body biosensors as force-multipliers, enabling real-time physiological awareness of troops. Critics note that the same technology, once developed, is available for broader population application.

Nano-Biosensors: The In-Body Frontier

The miniaturisation of biosensors to the nanoscale has transformed what is technically possible for in-body deployment. A nano-biosensor may be as small as tens of nanometres — well within the size range of particles deliverable by injection, inhalation, or transdermal absorption.

Key developments in nano-biosensor technology include:

• Carbon nanotube biosensors — single-walled carbon nanotubes (SWCNTs) functionalised with biological recognition molecules can operate inside living cells, detecting specific analytes by near-infrared fluorescence that passes through biological tissue.
• Infrared Quantum Dot biosensors — photostable, spectrally tunable semiconductor nanocrystals engineered to emit in the near-infrared window of biological tissue. IR quantum dots are increasingly incorporated into implantable and injectable biosensor platforms due to their ability to be interrogated transcutaneously, their long operational lifetime compared to organic fluorophores, and their compatibility with multiplexed detection schemes. Within the Internet of Bodies architecture, IR quantum dot sensors represent a compelling in-body optical layer that requires no internal power source — excitation is provided externally — while returning precise analyte data through centimetres of tissue. Toxicological concerns regarding heavy-metal-core formulations are addressed in detail under Nanotoxicology.
• Carbon Quantum Dot biosensors — carbon-derived fluorescent nanoparticles offering a lower-toxicity profile than heavy-metal quantum dots. CQDs are capable of multiplexed simultaneous detection of biomarkers, metal ions, and pathogens, and are water-soluble and readily functionalised. Their biocompatibility makes them candidates for long-term injectable biosensor configurations. See Nanotoxicology for current assessment of CQD safety in biological systems.
• Conventional semiconductor quantum dot biosensors — cadmium- and indium-based quantum dots used as optical labels for biosensing within cells and tissues; now increasingly being displaced in research settings by carbon-based alternatives on toxicological grounds.
• DNA nanotechnology biosensors — engineered DNA structures that act as molecular switches, reconfiguring in the presence of a target analyte and producing a detectable signal.
• Graphene Oxide biosensors — graphene oxide and reduced graphene oxide have become the substrate of choice for nano-electrochemical biosensors due to their high surface area, ease of functionalisation, and electrical properties. Research published in peer-reviewed literature demonstrates graphene-oxide-based electrochemical biosensors capable of detecting nucleic acids, proteins, and small molecules at femtomolar concentrations.

According to researchers including Dr. Ana Maria Mihalcea and the team at La Quinta Columna, structures consistent with graphene-based electrochemical biosensors have been identified in live blood analysis of individuals who received COVID-19 vaccines. These claims remain contested by mainstream bodies but have prompted independent investigation into whether injectable pharmaceutical products could serve as covert delivery mechanisms for nano-biosensor components.

The Human Body as a Sensor Platform

The Internet of Bodies (IoB) framework — explicitly discussed in academic and policy literature including papers from the RAND Corporation — envisions the human body as a networked sensor node. In this framework:

• Implanted and ingested biosensors continuously sample physiological parameters
• Data is transmitted via Body Area Network and Body Sensor Network protocols to edge devices (smartphones, wearables) and thence to cloud infrastructure
• Aggregated biological data feeds into population health monitoring, behavioural prediction, and — according to critics — social control systems

The MICS Band (Medical Implant Communications Service), operating at 402–405 MHz, is the designated spectrum for implanted biosensor telemetry. This band is specifically regulated for low-power transmission from inside the body, confirming that regulatory and technical infrastructure for in-body biosensor networks already exists.

The Intra-Body Nano Network concept extends this further: if nano-biosensors are deployed in sufficient density within the body, they could form a self-organising mesh network capable of routing biosensor data outward via a gateway device without the subject's awareness or consent.

Analogies in Civilian Sensing Infrastructure

Some researchers draw a parallel between covert biosensor deployment and the rollout of SMART Meters — utility monitoring devices installed in homes ostensibly for energy management, but which collect high-resolution data on occupant behaviour, appliance use, and daily routines. Like nano-biosensors proposed within the IoB framework, smart meters:

• Operate continuously without active user engagement
• Transmit data wirelessly to centralised aggregation systems
• Were rolled out under a civilian benefit rationale (energy efficiency, health monitoring) while their secondary data uses were not fully disclosed to the public
• Have been subject to legal challenges regarding consent, privacy, and electromagnetic exposure

The analogy illustrates a broader pattern: sensing infrastructure with genuine civilian utility is simultaneously capable of functioning as a surveillance and social profiling tool. Critics argue the same logic applies — at a more intimate scale — to biosensors incorporated into pharmaceutical products or implanted under a medical rationale.

Smart meters: civilian sensing infrastructure with acknowledged dual data-collection capabilities, analogous in principle to proposed in-body biosensor networks.

Biosurveillance at Population Scale

When biosensor data from millions of individuals is aggregated, the surveillance implications become qualitatively different from any previous monitoring technology:

• Real-time physiological state of populations — stress levels, immune responses, neurochemical states — could be monitored continuously
• Anomalous readings could flag individuals for automated intervention or targeting
• Biological data could be correlated with location, communication, and behavioural data to build comprehensive profiles

Biosurveillance programmes at national level — including those coordinated through the WHO and national public health agencies — are already frameworks for population biological monitoring. Critics such as Catherine Austin Fitts argue that the convergence of nano-biosensors, digital identity systems, and financial infrastructure is not coincidental but represents a coherent architecture of control aligned with the Transhumanist Agenda.

Nanotoxicology of Biosensor Materials

The deployment of nanomaterial-based biosensors — whether in disclosed clinical devices or in hypothesised covert configurations — raises important toxicological questions examined under Nanotoxicology:

• Heavy-metal quantum dots (cadmium selenide, lead sulphide, mercury telluride) are recognised cytotoxins. Their long-term fate in biological tissue — whether sequestered, metabolised, or released as ionic heavy metals — is not definitively established. Regulatory approvals for in-body use of such materials remain limited.
• IR Quantum Dots based on indium arsenide or similar III-V semiconductors present a somewhat more favourable profile than cadmium-based variants, but arsenic release during degradation remains a concern under Nanotoxicology review.
• Carbon Quantum Dots derived from organic precursors generally demonstrate lower acute toxicity in cell culture and animal studies, making them the preferred direction for next-generation injectable biosensor development where biocompatibility is prioritised.
• Graphene Oxide at biosensor-relevant concentrations has been associated with oxidative stress, membrane disruption, and inflammatory responses in cell models, with dose and surface chemistry being critical determinants of toxicity.
• Carbon nanotubes have well-documented pulmonary toxicity via inhalation pathways; their behaviour when injected and lodged in tissue long-term is subject to ongoing investigation.

Researchers argue that the absence of long-term Nanotoxicology data for many of these materials, combined with their incorporation into mass-administered products, represents a significant unresolved public health question.

Concerns About Undisclosed Deployment

Several researchers have raised specific concerns about biosensor components potentially present in injectable and other pharmaceutical products without disclosure:

• Ricardo Delgado and Dr. Pablo Campra of La Quinta Columna published microscopy analysis of COVID-19 vaccine vials claiming to identify graphene oxide structures. Graphene oxide is a core substrate for electrochemical biosensors.
• Mik Andersen (pseudonym, researcher Corona2Inspect) published detailed technical analysis suggesting that self-assembling nanostructures observed in vaccine preparations correspond to described components of intra-body nano-network architectures, including biosensor-like elements.
• Dr. Ana Maria Mihalcea has documented structures in live blood analysis that she describes as consistent with nanotechnology including potential biosensing components, present in both vaccinated and, increasingly, unvaccinated individuals — suggesting possible environmental or aerosol exposure pathways.

These claims are not validated by regulatory bodies. However, given the documented existence of graphene-based biosensor technology, IR quantum dot and carbon quantum dot biosensor platforms in the peer-reviewed literature, the regulatory approval of nano-containing formulations, and the DARPA investment in in-body sensor platforms, researchers argue the technical plausibility cannot be dismissed.

Connection to Targeted Individuals

Targeted Individuals frequently report physiological symptoms and monitoring experiences consistent with what would be expected if in-body biosensors were active and being used to guide directed interventions:

• Awareness of being physiologically monitored
• Correlation between physical symptoms and external stimuli
• Reports of biological data apparently being accessed by third parties
• Symptoms consistent with remote physiological modulation based on biosensor feedback

Remote Neural Monitoring and Remote Neural Modulation technologies, as described by researchers including Dr. Robert Duncan, imply closed-loop systems in which biosensor feedback informs and adjusts the targeting signal — a system that would require precisely the kind of in-body biosensor platform described in DARPA literature.

See Also

• Internet of Bodies
• Body Sensor Network
• Body Area Network
• MICS Band
• Intra-Body Nano Network
• Graphene Oxide
• Nanotechnology
• Nanotoxicology
• Biosurveillance
• DARPA
• DARPA Human Enhancement Programmes
• Targeted Individuals
• Transhumanist Agenda
• COVID Vaccines
• La Quinta Columna
• Dr. Ana Maria Mihalcea
• Remote Neural Monitoring
• IR Quantum Dots
• Carbon Quantum Dot
• Quantum Dots
• SMART Meters

References

• Thévenot, D.R. et al. (2001). "Electrochemical biosensors: recommended definitions and classification." Biosensors and Bioelectronics, 16(1–2), 121–131.
• DARPA PALS Programme Solicitation (2018). Persistent Aquatic Living Sensors. DARPA Biological Technologies Office.
• RAND Corporation (2020). The Internet of Bodies: Opportunities, Risks, and Governance.
• Andersen, M. [Corona2Inspect] (2021). "Identification of possible nano-network components in COVID-19 vaccines." Independent research publication.
• Campra, P. (2021). "Detection of graphene in COVID-19 vaccines by Micro-Raman Spectroscopy." University of Almería.
• Bhattacharya, K. et al. (2022). "Carbon quantum dots as fluorescent biosensors: a review." Journal of Materials Chemistry B, 10, 4751–4768.
• Medintz, I.L. et al. (2005). "Quantum dot bioconjugates for imaging, labelling and sensing." Nature Materials, 4, 435–446.
• Petryayeva, E. & Algar, W.R. (2013). "Toward point-of-care diagnostics with consumer electronic devices: the expanding role of nanoparticles." RSC Advances, 3(30), 12200–12220.